Death-associated protein kinase 2 (DAPK2) belongs to a family of proapoptotic Ca 2 þ /calmodulin-regulated serine/ threonine kinases. We recently identified DAPK2 as an enhancing factor during granulocytic differentiation. To identify transcriptional DAPK2 regulators, we cloned 2.7 kb of the 5 0 -flanking region of the DAPK2 gene. We found that E2F1 and Kru¨ppel-like factor 6 (KLF6) strongly activate the DAPK2 promoter. We mapped the E2F1 and KLF6 responsive elements to a GC-rich region 5 0 of exon 1 containing several binding sites for KLF6 and Sp1 but not for E2F. Moreover, we showed that transcriptional activation of DAPK2 by E2F1 and KLF6 is dependent on Sp1 using Sp1/KLF6-deficient insect cells, mithramycin A treatment to block Sp1-binding or Sp1 knockdown cells. Chromatin immunoprecipitation revealed recruitment of Sp1 and to lesser extent that of E2F1 and KLF6 to the DAPK2 promoter. Activation of E2F1 in osteosarcoma cells led to an increase of endogenous DAPK2 paralleled by cell death. Inhibition of DAPK2 expression resulted in significantly reduced cell death upon E2F1 activation. Similarly, KLF6 expression in H1299 cells increased DAPK2 levels accompanied by cell death that is markedly decreased upon DAPK2 knockdown. Moreover, E2F1 and KLF6 show cooperation in activating the DAPK2 promoter. In summary, our findings establish DAPK2 as a novel Sp1-dependent target gene for E2F1 and KLF6 in cell death response.
Introduction
The death-associated protein kinase 2 (DAPK2 or DRP-1) functions as a positive mediator of programmed cell death when overexpressed in various cellular backgrounds. Up to now, four other members of the DAPK family have been identified. DAPK1, the closest homolog of DAPK2, is suggested to act as a tumor suppressor (Bialik and Kimchi, 2006) and is epigenetically silenced in a variety of human cancers (Katzenellenbogen et al., 1999; Esteller et al., 2001; Maruyama et al., 2001; Voso et al., 2004; Christoph et al., 2006) . Similar to DAPK1, DAPK2 has been shown to participate in tumornecrosis factor-a and FAS-receptor-induced cell death (Inbal et al., 2000; Shohat et al., 2002) . Despite the obvious importance of this death-promoting kinase, a detailed analysis of the participating regulative mechanisms is still missing. We have recently shown that DAPK2 acts as an enhancer of neutrophilic maturation in myeloid leukemic cells (Rizzi et al., 2007) , underpinning its relevance in terminal cell differentiation. The molecular mechanisms that are responsible for regulation of the DAPK2 gene, however, remain unidentified.
In the present study, we analysed the transcriptional regulation of DAPK2. Based on in silico DNA sequence analysis, the promoter region upstream of exon 1 contains multiple motifs similar to E2F as well as KLF6 DNA binding sites. The predicted KLF6 binding sites are part of a GC box proximal to exon 1, and this GC-rich sequence also displays several putative Sp1 binding sites. As often seen for promoters bearing regulative GC-rich sequences (Blake et al., 1990) , no consensus TATA-box was found in the DAPK2 promoter region.
The E2F family of transcription factors are key regulators of genes involved in DNA replication, cellcycle control, apoptosis and oncogenic transformation. E2F1, the founding member of the family, plays a unique role among the E2Fs by regulating cellular growth in both a positive and negative manner. Besides its well-documented role of stimulating cell-cycle progression, it has more recently become apparent that E2F1 has the ability to induce apoptosis. E2F1-mediated cell death occurs in presence or absence of functional p53 and is regarded as a fail-safe mechanism in response to oncogenic hyperproliferation (Putzer, 2007) .
In addition to the E2F-binding motifs, the DAPK2 promoter region contains a GC box proximal to exon 1 with consensus binding sites for Kru¨ppel-like factor 6 (KLF6) and specificity protein 1 (Sp1). Both proteins are members of the same Kru¨ppel-like/Sp family of zinc finger transcription factors. KLFs regulate differentiation and development through their roles in signal transduction, cell proliferation, apoptosis and angiogenesis (Bieker, 2001; Black et al., 2001; Suzuki et al., 2005) . KLF6 is ubiquitously expressed and contains a highly conserved COOH terminus zinc finger DNAbinding domain that interacts with GC box motifs in target promoters, often containing no or only weak TATA-boxes (Turner and Crossley, 1999) . KLF6 is functionally inactivated in a variety of human cancers (Chen et al., 2003; Narla et al., 2003; Reeves et al., 2004; Difeo et al., 2006; Yin et al., 2007) and has been shown to induce apoptosis in non-small cell lung cancer (NSCLC) in a p53-independent manner (Ito et al., 2004) .
Sp1 accounts together with Sp3 for most of the GC-box binding activities in mammalian cells (Suske, 1999) . It has largely been recognized as a basal factor controlling initiation of transcription in TATA-less promoters (Kollmar et al., 1994) . Sp1 is essential for regulating a growing number of cell cycle and cancerrelated genes, as for example p21 (Koutsodontis and Kardassis, 2004) , p14 ARF (Parisi et al., 2002) , DHFR (Park et al., 2003) or MYCN (Kramps et al., 2004) . It often does so by interacting with other transcription factors at the sites of transcriptional initiation.
Because DAPK2 exhibits proapoptotic functions in cancer cells, we examined the transcriptional regulation of the DAPK2 gene by the potentially tumor-suppressive E2F1, KLF6 and Sp1 transcription factors. Our results indicate that, indeed, E2F1 and KLF6 activate DAPK2 transcription in an Sp1-dependent fashion. We further show that knocking down DAPK2 significantly dampens E2F1 and KLF6-induced cell death in a p53-dependent as well as -independent pathway. Finally, we found cooperative activation of the DAPK2 promoter by E2F1 and KLF6 most likely due to functional interactions of these two proteins.
Results
DAPK2 is activated by E2F1 by an Sp1/KLF6 binding sites cluster To identify candidate nuclear factors binding to the DAPK2 promoter region, DNA sequence alignment was performed to search for known transcription factors using MatInspector 7.0. Two putative transcription factor binding sites for E2F transcription factors were found. Given the role of E2F1 in apoptosis, we planned to measure the mRNA levels of the proapoptotic DAPK2 after E2F1 activation. To this end we used U2OS osteosarcoma cells expressing an E2F1-estrogen receptor fusion protein in which E2F1 was activated in response to 4-hydroxytamoxifen (OHT) treatment . Activation of E2F1 in U2OS-ER-E2F1 osteosarcoma cells significantly increased DAPK2 mRNA levels 3.6-fold ( Figure 1a) . As a control for successful E2F1 induction, we measured expression of cyclin E1, a well-known E2F1 target gene (Geng et al., 1996) in all experiments. Similarly, E2F1 activation in human diploid fibroblasts (TIG3) and its ectopic expression in H1299 NSCLCs led to a 2.6-and 3.3-fold increase of endogenous DAPK2 mRNA levels (data not shown).
Next, to characterize the mechanism of DAPK2 transcriptional activation by E2F1, we cloned a 2.7 kb fragment upstream of exon 1 (TSS ¼ 62125975 of ctg ¼ NC_000015 on chromosome 15) containing at least two potential E2F-binding sites into the pGL3 luciferase reporter vector. To identify the E2F responsive element, deletion constructs were generated comprising different sizes based on the prediction of E2F binding sites (Figure 1b , left panel) and were then transfected into H1299 cells together with an E2F1 expression plasmid. The full-length promoter construct (À2659/ þ 43) containing two predicted binding sites and the deletion construct bearing only one potential binding site close to the core promoter region (À329/ þ 43) were both activated to a similar extent (Figure 1b, right panel) . Surprisingly, a minimal DAPK2 promoter construct (À50/ þ 43) containing a GC-rich region upstream from exon 1, lacking all putative E2F binding sites, was still highly activated in response to E2F1 expression. In addition, mutation of the full-length promoter through deletion of this 93 bp GC-rich region produced a construct (À2659/À50) with basic activity but that was no longer responsive to E2F1 co-transfection (Figure 1b, right panel) . Further analysis of this 93 bp promoter region revealed a cluster of six and five putative binding sites for Sp1 and KLF6, respectively ( Figure 1c ). To further investigate the precise mechanism of this E2F1 and possibly Sp1-mediated activation of the DAPK2 promoter, we performed transactivation experiments in Schneider SL2 cells. These cells lack Sp1 and related activities and thus represent a useful system to study Sp1-mediated transcriptional responses. Overexpression of E2F1 alone was not sufficient to induce activity of the full-length promoter (À2659/ þ 43) and the deletion mutant (À50/ þ 43). In contrast, coexpression of E2F1 along with Sp1 restored the E2F1 responsiveness of the promoter constructs and resulted in synergistic transactivation, which was not seen when using the deletion mutant lacking the GC box ( Figure 1d) .
We next activated E2F1 in U2OS-ER-E2F1 cells and then blocked Sp1-binding to the DNA by mithramycin A treatment (Miller et al., 1987) . Indeed, we found that E2F1-mediated upregulation of DAPK2 mRNA was dose-dependently reduced upon mithramycin A treatment (from 6.7-to 5.3-fold and 2.8-fold), whereas cyclin E1 control mRNA was not (Figure 1e ). Finally, we knocked down Sp1 in U2OS-ER-E2F1 cells using RNA interference and then activated E2F1. DAPK2 was 5.4- 
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A Britschgi et al fold upregulated in control SHC002 cells ( Figure 1f , left panel) but not in either of the Sp1 knockdown cells (Mix1 and Mix2, 1.8 and 1.7-fold, respectively). In the control experiment, induction of cyclin E1 mRNA levels was not significantly affected by inhibition of Sp1. Sp1 knockdown was confirmed by western blotting (Figure 1f , right panel). Taken together, our findings suggest that E2F1 activates DAPK2 through an Sp1/ KLF6 binding site cluster within the proximal promoter region of the kinase and that this activation is dependent on Sp1 expression.
KLF6 induces DAPK2 by Sp1
Based on our results from the initial promoter screening experiments and data presented above, we decided to investigate the activation of DAPK2 by the Sp-like factor, KLF6. We chose H1299 NSCLCs for KLF6 expression studies, because these cells show low endogenous KLF6 levels. Further, ectopic KLF6 expression has been shown to induce apoptosis in these cells (Ito et al., 2004) . Transient transfections of KLF6 into H1299 NSCLCs led to a 2.8-fold upregulation of endogenous DAPK2 message compared to the empty vector control (Figure 2a ). KLF6 mRNA was quantified to test for successful transfection. We next performed luciferase assays in H1299 cells co-transfecting KLF6 expression plasmid or empty vector together with (À2659/ þ 43) and (À50/ þ 43) DAPK2 promoter constructs. Both DAPK2 promoter constructs were activated by KLF6 expression. A mutated promoter construct lacking the GC box was not induced upon KLF6 expression indicating that the GC box represents the KLF6-responsive element ( Figure 2b ). To test for a possible role of Sp1 in KLF6-induced DAPK2 promoter activity, Sp1/KLF6-negative Schneider SL2 cells were co-transfected with Sp1 and KLF6. Despite potential KLF6 binding sites present in the GC box, KLF6 did not activate the DAPK2 promoter in the absence of Sp1 ( Figure 2c ). In line, inhibition of Sp1 binding by mithramycin A treatment (Figure 2d ) or knocking down Sp1 using RNA interference completely abolished KLF6-mediated upregulation of DAPK2 mRNA in H1299 cells (Figure 2f , left panel). Sp1 knockdown efficiency was measured by western blotting (Figure 2f , right panel). In both experiments, equal transfection efficiency was assessed by measuring KLF6 mRNA (Supplementary Figure 1a and b) . In summary, KLF6-induced activation of DAPK2 is strictly dependent on Sp1 despite putative KLF6 binding sites in the GC box.
Sp1, E2F1 and KLF6 binding to the DAPK2 promoter The À50 to þ 27 region of the DAPK2 promoter was tested for in vitro binding to E2F1, Sp1 and KLF6 using band shift assays. Electrophoretic mobility shift assay (EMSA) of HEK293T nuclear lysates and annealed g-32 P GC box oligonucleotides was performed (Figure 3a) . Supershift assays of the bound oligonucleotide probe were carried out using antibodies against KLF6, Sp1, E2F1 and CBP/p300, an acetylase shown to be associated with KLF6 enhancing its binding to target sequences (Li et al., 2005; Figure 3a , lanes 3-6). Only the antiserum against Sp1 resulted in a clear supershift of the bound probe (Figure 3a , lane 4, depicted with **), although a reduction of the bound probe was seen with the E2F1 antibody and no change in binding was observed with the KLF6 antibody. These experiments indicate that Sp1 is the predominant factor binding to the GC box.
Chromatin immunoprecipitation (ChIP) assays were carried out to test whether Sp1, E2F1 and KLF6 bind to the DAPK2 promoter in vivo. Nuclear lysates from Sp1, E2F1 and KLF6 co-transfected HEK293T were used for pull-downs with Sp1, E2F1 and KLF6 antibodies. Precipitated chromatin was used to amplify a 150 bp fragment of the proximal DAPK2 promoter containing the GC box. Sp1 strongly associated with the GC box in the DAPK2 promoter, whereas only weak binding of E2F1 and KLF6 was observed (Figure 3b , upper panel). As negative control for the ChIP assay, we used primers that amplify a region 1.6 kb downstream of the GC Box ( Figure 3b , lower panel). To conclude, these binding assays suggest that all the three transcription factors, Sp1, E2F1 and KLF6, are present at the DAPK2 promoter.
DAPK2 knockdown attenuates E2F1 and KLF6-induced cell death
Both E2F1 and KLF6 have the potential to induce cell death. Thus, we next investigated whether knocking down the proapoptotic DAPK2 kinase by RNA interference would have any consequences on E2F1-or KLF6-induced cell death. Induction of E2F1 in U2OS-ER-E2F1 cells resulted in 20% cell death in the small hairpin (sh)RNA targeting Firefly luciferase (shFluc) expressing control cells as measured in XTT assays, whereas cell death in DAPK2 knockdown cell lines was only 12 and 11%, respectively (Figure 4a ). Similarly, a significant reduction of cell death was seen by staining apoptotic cells using Annexin V (Figure 4b Figure 2a) . Western blotting of nuclear extracts showed equal efficiency of E2F1 translocation into the nucleus in all the three cell lines (Figure 4d, lower panel) .
For analysis of KLF6-induced cell death, we transiently transfected H1299 cells with KLF6 or the empty vector as control. H1299 SHC002 control cells displayed 23.2% cell death after 48 h, whereas knocking down DAPK2 resulted in a significant reduction of cell death of 12.1 and 14.8%, respectively (Figure 4e ). These findings were supported by staining for early apoptosis (Figure 4f ) and by measuring caspase 7/8 activities (Figure 4g ). Upregulation of DAPK2 and knockdown efficiency were measured by western blotting (Figure 4h 
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E2F1 and KLF6 cooperate in activating DAPK2
To examine a potential cooperation between E2F1 and KLF6 in modulating DAPK2 promoter activity, Schneider SL2 cells were transfected with each of the expression vectors encoding E2F1, KLF6 or both, together with the GC-box DAPK2 promoter reporter (À50/ þ 43) and the GC-box deletion mutant (À2659/ À50). As we previously showed that E2F1 and KLF6 activation of the DAPK2 promoter is Sp1-dependent, an Sp1 expression plasmid was co-transfected in each reporter assay. Luciferase assays revealed that KLF6 and E2F1 activated the GC-box DAPK2 promoter reporter 12-and 20-fold, respectively. Combined expression of KLF6 and E2F1 led to a 52-fold activation indicating that these two transcription factors cooperate in activating the DAPK2 promoter (Figure 5a ). In line with these data, we found that simultaneous induction of E2F1 and transfection of KLF6 resulted in a significantly higher upregulation of DAPK2 mRNA in U2OS-ER-E2F1 cells than each treatment alone (Figure 5b ). Finally, we examined a possible interaction of endogenous KLF6 and E2F1 using nuclear extracts from human B-cell precursor leukemia REH cells. These extracts were subjected to immunoprecipitation (IP) using anti-KLF6 and anti-c-jun antibodies, then KLF6 and E2F1 western blotting of the electrophoresed IP were performed. As low KLF6 and E2F1 protein levels in crude lysates of REH cells could not be detected after stripping of the membrane, we show two different KLF6 IPs, one probed with anti-KLF6 and the other with anti-E2F1 antibody. C-jun has been shown to interact with KLF6 (Slavin et al., 2004) and served as a positive control for the IP. As shown in Figure 5c , immunoblotting with E2F1 antibody identified E2F1 in the anti-KLF6 immunoprecipitates demonstrating that KLF6 and E2F1 can be in the same protein complex.
Discussion
Previously, we found that DAPK2 is important for myeloid development and that it is suppressed in acute myeloid leukemic blast cells, suggesting that DAPK2 displays tumor suppressor activities (Rizzi et al., 2007) . The aim of the present study was to identify transcriptional regulators of this putative tumor suppressor. Computational analysis of the proximal DAPK2 promoter spanning 2.7 kb upstream of the first exon revealed possible E2F and KLF6 binding sites. We found activation of E2F1 increased DAPK2 message in various cancer cell types. The amount of DAPK2 upregulation upon E2F1 activation in U2OS-E2F1-ER cells was identical to inductions seen for other known E2F targets such as Apaf-1 or the BH3-only proteins PUMA/Noxa (Hershko and Ginsberg, 2004) . KLF6 most efficiently induced DAPK2 in H1299 NSCLC cells. This might be attributed to the fact that these cells as well as primary NSCLC samples (Ito et al., 2004 ) show very low base-level expression of KLF6.
Luciferase reporter assays using DAPK2 promoter deletion mutants showed that a GC box proximal to exon 1 is the E2F1 and KLF6-responsive element. Reporter assays in an Sp/KLF-negative cellular background, as well as inhibition of DAPK2 activation by blocking Sp1 binding by mithramycin A treatment or by knocking down Sp1 using RNA interference further revealed that activation of DAPK2 is dependent on direct binding of Sp1 to the promoter. Together with our ChIP results showing only weak binding of both, E2F1 and KLF6, to the DAPK2 promoter compared to the readily detectable Sp1, we suggest that binding of E2F1 and KLF6 to the DAPK2 promoter is indirect. This might at first sight be surprising, because both E2F1 and KLF6 could-based on computational analysis-bind directly to the promoter. On the other hand, E2F1 is an Sp1 binding partner and its cell-cycle regulated association with Sp1 has been proposed to be important for fine tuning the transcription of respective target genes (Karlseder et al., 1996; Lin et al., 1996) . Similarly, Sp1 interaction with its close relative KLF6 is essential for activation of GC-rich promoters (Kim et al., 1998; Botella et al., 2002) .
We now found that Sp1 is needed for inducible DAPK2 expression by E2F1, a mechanism that is not (a) Gel electrophoretic mobility shift assays using g-32 P-labeled, double-stranded, oligonucleotide probes corresponding to the GC-rich box incubated with nuclear extracts from HEK293T cells, bandshifts are depicted with (*). Protein/DNA complexes were supershifted (**) with antibodies as indicated. (b) Chromatin immunoprecipitation (ChIP) assays using HEK293T cells transiently transfected with Sp1, E2F1 and KLF6 expression plasmids and antisera against Sp1, E2F1 and KLF6. Anti-Pol II and IgG served as positive and negative controls, respectively. PCR was performed using primers encompassing the GC box in the DAPK2 promoter and an unrelated sequence 1.6 kb downstream of the GC box as a negative control.
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A Britschgi et al without precedent; for example, E2F1-mediated induction of the ARF tumor suppressor is regulated by several Sp1 and E2F binding sites (Robertson and Jones, 1998; Parisi et al., 2002) . Regarding KLF6-mediated, Sp1-dependent activation of DAPK2, our data are in line with earlier reports showing physical interaction of SP1 and KLF6/Zf9 in activation of transforming growth factor-b and endoglin (Kim et al., 1998; Botella et al., 2002) . Although KLF6 and Sp1 have highly similar DNA recognition sites, both may be present at GC-rich promoters, stabilizing each other, recruiting additional factors and thus building a transcriptional network enabling the cell to respond flexibly to various signals. In favor of this hypothesis, we show that the DAPK2 promoter and endogenous DAPK2 message were synergistically activated by E2F1 and KLF6 upon co-transfection. In addition, we found in vivo binding of E2F1 and KLF6, pointing to a possible mechanism on how these transcription factors cooperate in activating DAPK2. We suggest that the observed transcriptional activation through E2F1 and KLF6 is important for full activation of the DAPK2 promoter, adding KLF6 as a further player to E2F1-Sp1-dependent transcription of a gene regulating cell death.
Nevertheless, we would like to refrain from simply adding KLF6 to other components of the general transcription machinery, although KLF6-mediated, Sp1-dependent activation of DAPK2 might have important biological effects in specific cell types and cellular contexts. For example, KLF6 expression is low in prostate cancer cells and its induction allows 
A Britschgi et al upregulation of the p21 CIP1 cell-cycle inhibitor in a p53-independent fashion (Narla et al., 2001) . Furthermore, KLF6 also induces cell death in p53-negative NSCLC H1299 cells without upregulating p21 CIP1 (Ito et al., 2004) . So far, the cell death mechanism in the latter study remained largely unknown. But we now show that KLF6-mediated cell death in NSCLC H1299 cells is markedly reduced upon knocking down DAPK2 and thus identify this proapoptotic kinase as an important KLF6 target gene through which p53-independent cell death can be accomplished.
E2F1 has been shown to play a dual role in either promoting proliferation or cell death depending on the cellular context, the E2F1 levels and its activating signals (DeGregori and Johnson, 2006) . Its ability to induce apoptosis is unique among the E2F family members (Denchi and Helin, 2005) and is a part of an antitumor safeguard mechanism. There are multiple roads to E2F1-induced cell death: (a) p53 dependent through transactivation of ARF, PUMA and Noxa or DAPK1, or (b) p53 independent through activation of p73, Smac/DIABLO, DIP, Apaf-1 and caspase 7 or inhibition of NF-kB (Bell and Ryan, 2003) . To evaluate the causative role of DAPK2 in E2F1-induced cell death, we knocked down DAPK2 in U2OS-ER-E2F1 osteosarcoma cells using RNA interference. We found that DAPK2 knockdown cells are significantly protected from E2F1-induced cell death. The levels of cell death reduction in the present study (from 20% in the control cell line to 12 and 11% in the knockdown cell lines, that is 40 and 45% of reduction) were similar to the reduction levels seen in inhibition experiments of other E2F1 target genes, for example 45% for p73 (Irwin et al., 2000) , 35% for Smac/DIABLO (Xie et al., 2006) , 35% for Noxa (Hershko and Ginsberg, 2004) , 60% for Apaf-1 or 50% for DIP (Stanelle et al., 2005) . The present study now adds the proapoptotic kinase DAPK2 to the list of E2F1-targeted cell death genes and shows its critical role in E2F1-induced cell death.
In summary, based on our results and reports published by others we present the following model of transcriptional DAPK2 regulation (Figure 5d ). We suggest that Sp1 is indispensable for basic DAPK2 
A Britschgi et al promoter activity and that E2F1 and KLF6 are needed for further regulation. We postulate binding of a tripartite Sp1-KLF6-E2F1 complex to the DAPK2 promoter GC box, but cannot exclude sequential binding of Sp1 and KL6 to the GC box. The observed, Sp1-dependent transactivation by KLF6 and E2F1 could be a result of enhanced binding that leads to more efficient initiation of transcription. Finally, emphasizing the role of DAPK2 in different cell death pathways, we showed that DAPK2 is a critical downstream target in E2F1-and KLF6-induced cell death.
Materials and methods
Cell culture H1299 NSCLC, HEK293T and REH B-cell precursor leukemia cell lines were purchased from the American Type Culture Collection (ATCC-LGC Promochem, Molsheim, France). Tamoxifen-inducible U2OS-ER-E2F1 cells were generated as described elsewhere . Cells were maintained in RPMI-1640 or Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 50 U/ml penicillin and 50 mg/ml streptomycin. Early passage Schneider (SL2) cells were kindly provided by D. Kojic (Institute of Cell Biology, University of Bern) and maintained in Drosophila's Schneider Insect Medium (SigmaAldrich, Buchs, Switzerland) supplemented with 10% FCS, 50 U/ml penicillin and 50 mg/ml streptomycin without any gas exchange at 25 1C.
DAPK2 promoter constructs
A 2.7 kb genomic fragment 5 0 of exon 1 was PCR-amplified from genomic DNA of human leukocytes using the GC-RICH PCR System (Roche Diagnostics, Rotkreuz, Switzerland) and subloned into pGL3-basic Luciferase vector (Promega Corporation, Madison, WI, USA) using standard cloning techniques. Primer sequences are available upon request.
Lentiviral knockdown constructs
Lentiviral vectors expressing shRNAs are given in Supplementary Table 1 . Lentivirus production, titer determination and transduction were carried out as described (Tschan et al., 2003; Rizzi et al., 2007) .
Reporter assays and transient transfections H1299 and Schneider SL2 cells were transfected with Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen, Carlsbad, CA, USA). Cells were transfected with 200 ng reporter, 400 ng effectors and 10 ng of phRL-TK or 20 ng phRL-CMV (for SL2) expression plasmid for Renilla luciferase (Promega Corporation) and lysed 24 h after transfection. Reporter expression was analysed using the DualLuciferase Reporter Assay System (Promega Corporation). In all transient KLF6 expression experiments, the p300/CBP acetylase was co-transfected, because it has been described to be critical for full KLF6 activity (Li et al., 2005) . The Firefly luciferase activity of each sample was normalized to its Renilla luciferase activity and the fold activation was obtained by setting the value of empty vector control as 1.0.
A total of 1.5 Â 10 6 U2OS-ER-E2F1 cells were plated in 10 cm dishes, starved for 24 h and then induced for 6 h with 600 nM of 4-hydroxytamoxifen. H1299 cells were transfected in 10 cm dishes with 12 mg of expression plasmids (E2F1, KLF6 and CBP/p300, empty vector control pcDNA3.1) with Lipofectine according the manufacturer's protocol (Invitrogen).
Real-time quantitative reverse transcription-PCR Total RNA was extracted using the RNeasy Mini Kit and the RNase-Free DNase Set according to the manufacturer's protocol (Qiagen, Hombrechtikon, Switzerland). Total RNA was reverse transcribed using random primers (Roche Diagnostics) and M-MLV reverse transcriptase (Promega Corporation). PCR and fluorescence detection were performed using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland).
For quantification of DAPK2, KLF6 and cyclin E1 mRNA TaqMan Gene Expression Assays Hs00204888_m1, Hs00810569_m1 and Hs01026536_m1 (Applied Biosystems) were used. HMBS primers and probes have been described (Britschgi et al., 2006) . n-Fold changes were calculated using the DDCt method of relative quantification.
Immunoprecipitation and western blot analysis IP, immunoblotting and nuclear protein extraction have been described previously (Andrews and Faller, 1991; Radziwill et al., 2003) . Primary antibodies used were anti-DAPK2 (2323; ProSci, Poway, CA, USA), anti-E2F1 (sc-251 X), anti-KLF6 (sc-7158 X), anti-Sp1 (PEP 2, sc-59 X) and anti-c-Jun (sc-1694; Santa Cruz Biotechnology, Heidelberg, Germany). Secondary antibodies used were donkey antirabbit and sheep antimouse horseradish peroxidase-conjugated immunoglobulin (IgG) (Amersham, Zurich, Switzerland)
Electrophoretic mobility shift assay Single-stranded oligonucleotides (GC box of DAPK2 promoter, forward: 5 0 -CCGCCGCGCCCGCCGCGCCCGCCGCGCC CGCCGCGCCCGCCGCGCCCGCC-3 0 , reverse: 5 0 -GGCG GGCGCGGCGGGCGCGGCGGGCGCGGCGGGCGCGG CGGGCGCGGCGG-3 0 ) were subjected to band shift assays as described (Britschgi et al., 2006) . Anti-KLF6 (sc-7158 X), anti-Sp1 (sc-59 X), anti-E2F1 (sc-251 X) and anti-CBP/p300 (sc-584 X) were used for supershifts.
Chromatin immunoprecipitation
For ChIP assays, HEK293T cells were transfected with 2 mg Sp1, E2F1 and KLF6 expression plasmids using Lipofectine (Invitrogen). The assays were carried out according to the ChIP-IT Express protocol (Active Motif, Rixensart, Belgium) except for increased crosslinking time to enhance the chance of detecting indirectly associated proteins. Following DNA purification, PCR was performed using Hot Start Polymerase (Fermentas, Nunningen, Switzerland) and the following primers: DAPK2 promoter forward: 5 0 -TCTGGGAGGA GAGGACTGCA-3 0 , reverse: 5 0 -TACTCACGGCGGGAGG CTGA-3 0 ; negative control primers amplifying 188 bp region (genomic contig 15q22, 35127150-35127338) forward: 5 0 -GGTGGCTATCAACAGAAGAA-3 0 , reverse: 5 0 -ACTATAT GTTGGCGTTCTGG-3 0 .
Cell death assays U2OS-ER-E2F1 cells were synchronized for 24 h, followed by E2F1 induction with 600 nM OHT for 24 h. H1299 cells grown in 10 cm plates were transfected with 10 mg of pCI-neo KLF6 expression plasmid or an empty vector control using Lipofectine (Invitrogen). For XTT assays (Biological Industries, Kibbutz Beit Haemek, Israel) cells were seeded in triplicate, incubated as indicated by the manufacturer and absorbance DAPK2 is regulated by E2F1 and KLF6 A Britschgi et al was measured at 500 nm. For Annexin V staining, 0.5 Â 10 6 cells were washed with cold phosphate buffer solution/10% FCS, resuspended in 70 ml of Annexin V binding buffer, and prepared according to the manufacturer's protocol (BioVision, Mountain View, CA, USA) and at least 10 4 cells per sample were analysed by flow cytometry. Caspase 3/7 activation was measured using Caspase-Glo 3/7 Assay (Promega Corporation).
Statistical analysis
Each value reported represents the mean ± s.d. of at least four measurements of at least two independent experiments. Nonparametric Mann--Whitney U-tests were applied using the program JMP4 (SAS, Cary, NC, USA). P-values o0.05 were considered to be statistically significant.
